Company Overview - Emperor International Investment Limited is a Hong Kong-listed company focused on precision oncology and genetic testing [2] - The company provides molecular diagnostic solutions and academic research services for clinical doctors, hospitals, cancer patients, high-risk health individuals, and researchers in cancer-related fields [2] - The company has developed genetic testing products covering various types of tumors, including respiratory, digestive, breast, gynecological, urinary, and head and neck tumors, facilitating early screening, auxiliary diagnosis, medication guidance, prognosis assessment, and dynamic monitoring throughout the cancer management process [2] Financial Performance - As of September 30, 2024, Emperor International Investment reported total revenue of 33.534 million yuan, a year-on-year decrease of 55.43% [1] - The company recorded a net profit attributable to the parent of -1.4311 million yuan, a year-on-year decrease of 193.74% [1] - The gross profit margin stood at 2.71%, and the debt-to-asset ratio was 21.08% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.3 times, with a median of 5.39 times [1] - Emperor International Investment has a P/E ratio of 10.33 times, ranking 28th in the industry [1] - Comparatively, other companies in the health sector have significantly lower P/E ratios, such as Great Health International at 0.56 times and King’s Ray Biotechnology at 1.25 times [1]
帝王国际投资（00928.HK）6月4日收盘上涨10.0%，成交25.44万港元